Landmark pancreatic cancer drug shows potential against lung cancer too

TL;DR - Nature reports that daraxonrasib, a landmark pancreatic cancer drug, has also shown potential against lung cancer, raising hopes that it could work across multiple tumour types. The provided excerpt does not include study design, efficacy, or safety data.

• The reported findings concern extending daraxonrasib beyond pancreatic cancer to lung cancer.
• The results support investigating the drug as a treatment for a broader range of tumours.
• No quantitative outcomes, trial phase, patient population, or mechanism details are provided in the excerpt.